JP6635945B2 - 多動性運動障害を処置するためのｖｍａｔ２インヒビター - Google Patents

多動性運動障害を処置するためのｖｍａｔ２インヒビター Download PDF

Info

Publication number
JP6635945B2
JP6635945B2 JP2016566238A JP2016566238A JP6635945B2 JP 6635945 B2 JP6635945 B2 JP 6635945B2 JP 2016566238 A JP2016566238 A JP 2016566238A JP 2016566238 A JP2016566238 A JP 2016566238A JP 6635945 B2 JP6635945 B2 JP 6635945B2
Authority
JP
Japan
Prior art keywords
htbz
pharmaceutical composition
composition according
hexahydro
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016566238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514850A5 (cg-RX-API-DMAC7.html
JP2017514850A (ja
Inventor
クリストファー エフ． オブライエン，
クリストファー エフ． オブライエン，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド, ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2017514850A publication Critical patent/JP2017514850A/ja
Publication of JP2017514850A5 publication Critical patent/JP2017514850A5/ja
Application granted granted Critical
Publication of JP6635945B2 publication Critical patent/JP6635945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016566238A 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター Active JP6635945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181949A Division JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Publications (3)

Publication Number Publication Date
JP2017514850A JP2017514850A (ja) 2017-06-08
JP2017514850A5 JP2017514850A5 (cg-RX-API-DMAC7.html) 2018-06-14
JP6635945B2 true JP6635945B2 (ja) 2020-01-29

Family

ID=53264772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016566238A Active JP6635945B2 (ja) 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Country Status (24)

Country Link
US (3) US20170071932A1 (cg-RX-API-DMAC7.html)
EP (3) EP4389227A3 (cg-RX-API-DMAC7.html)
JP (4) JP6635945B2 (cg-RX-API-DMAC7.html)
KR (5) KR20220140647A (cg-RX-API-DMAC7.html)
CN (3) CN112741836A (cg-RX-API-DMAC7.html)
AU (1) AU2015256012B2 (cg-RX-API-DMAC7.html)
CA (1) CA2947736C (cg-RX-API-DMAC7.html)
CY (1) CY1125058T1 (cg-RX-API-DMAC7.html)
DK (2) DK3936130T3 (cg-RX-API-DMAC7.html)
ES (2) ES2976207T3 (cg-RX-API-DMAC7.html)
FI (1) FI3936130T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240459T1 (cg-RX-API-DMAC7.html)
HU (2) HUE057839T2 (cg-RX-API-DMAC7.html)
IL (1) IL248745B (cg-RX-API-DMAC7.html)
LT (2) LT3139925T (cg-RX-API-DMAC7.html)
MX (1) MX387625B (cg-RX-API-DMAC7.html)
NZ (1) NZ725826A (cg-RX-API-DMAC7.html)
PL (2) PL3936130T3 (cg-RX-API-DMAC7.html)
PT (2) PT3936130T (cg-RX-API-DMAC7.html)
RS (2) RS65359B1 (cg-RX-API-DMAC7.html)
RU (1) RU2753740C2 (cg-RX-API-DMAC7.html)
SI (2) SI3936130T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400199T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015171802A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531963A (ja) * 2015-10-30 2018-11-01 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
CN109153676B (zh) * 2016-06-29 2021-08-10 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
EA201991782A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2022104034A (ru) * 2017-04-01 2022-03-05 Адептио Фармасьютикалз Лимитед Фармацевтические композиции
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2771164C2 (ru) * 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019074492A1 (en) * 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
US11306082B2 (en) * 2017-11-08 2022-04-19 Foresee Pharmaceuticals Co., Ltd. Esters of dihydrotetrabenazine
WO2019129100A1 (zh) 2017-12-26 2019-07-04 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
IL320987A (en) 2018-08-15 2025-07-01 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
EP3965764A1 (en) * 2019-05-09 2022-03-16 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2081929E (pt) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
NO3061760T3 (cg-RX-API-DMAC7.html) 2008-09-18 2018-04-07
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
NZ705372A (en) 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (ru) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531963A (ja) * 2015-10-30 2018-11-01 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体
JP7109360B2 (ja) 2015-10-30 2022-07-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体

Also Published As

Publication number Publication date
CY1125058T1 (el) 2023-06-09
CN106456629A (zh) 2017-02-22
MX387625B (es) 2025-03-18
US20210196702A1 (en) 2021-07-01
NZ725826A (en) 2023-05-26
US20200101063A1 (en) 2020-04-02
KR20160147044A (ko) 2016-12-21
EP3936130A1 (en) 2022-01-12
RU2016147523A3 (cg-RX-API-DMAC7.html) 2018-12-28
US20170071932A1 (en) 2017-03-16
IL248745B (en) 2022-07-01
HRP20220025T1 (hr) 2022-04-01
RS65359B1 (sr) 2024-04-30
KR20250029267A (ko) 2025-03-04
KR20220140647A (ko) 2022-10-18
AU2015256012B2 (en) 2020-07-23
IL248745A0 (en) 2017-01-31
RU2016147523A (ru) 2018-06-08
JP2024153782A (ja) 2024-10-29
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
LT3139925T (lt) 2022-01-25
EP4389227A2 (en) 2024-06-26
PT3139925T (pt) 2022-01-26
CA2947736A1 (en) 2015-11-12
SMT202200193T1 (it) 2022-07-21
DK3139925T3 (da) 2021-12-20
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
SI3936130T1 (sl) 2024-05-31
RS62782B1 (sr) 2022-01-31
PT3936130T (pt) 2024-04-17
KR20200133003A (ko) 2020-11-25
EP3936130B1 (en) 2024-02-14
RU2753740C2 (ru) 2021-08-23
JP2021191799A (ja) 2021-12-16
CN112741836A (zh) 2021-05-04
WO2015171802A1 (en) 2015-11-12
JP2017514850A (ja) 2017-06-08
PL3139925T3 (pl) 2022-03-21
JP2019218407A (ja) 2019-12-26
EP3139925A1 (en) 2017-03-15
KR20240011255A (ko) 2024-01-25
CA2947736C (en) 2023-04-18
HUE066361T2 (hu) 2024-07-28
MX2016014429A (es) 2017-04-06
SI3139925T1 (sl) 2022-04-29
HUE057839T2 (hu) 2022-06-28
EP4389227A3 (en) 2024-09-04
ES2976207T3 (es) 2024-07-26
DK3936130T3 (da) 2024-03-25
LT3936130T (lt) 2024-04-25
CN112741835A (zh) 2021-05-04
HRP20240459T1 (hr) 2024-06-21
FI3936130T3 (fi) 2024-04-23
PL3936130T3 (pl) 2024-06-10

Similar Documents

Publication Publication Date Title
JP6635945B2 (ja) 多動性運動障害を処置するためのｖｍａｔ２インヒビター
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
US20170071975A1 (en) Compositions and methods for treating depressive disorders
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191217

R150 Certificate of patent or registration of utility model

Ref document number: 6635945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250